following a full submission
carbetocin (Pabal®) is not recommended for use within NHS Scotland.
Indication under review: For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.
A double-blind, randomised, controlled study in 377 women undergoing Caesarean section demonstrated a significant reduction in additional uterotonic treatment in women receiving carbetocin compared with oxytocin, although this result was not supported by two smaller double-blind, randomised, controlled studies.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice231KB (PDF)
- Medicine name:
- carbetocin (Pabal)
- SMC ID:
- For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Not recommended
- Date advice published
- 15 January 2018